Dermatology · Nebraska
Dermatology and skin studies in Nebraska
13 studies have at least one recruiting site in Nebraska. Skin studies test treatments for conditions such as psoriasis, eczema, acne, alopecia, vitiligo and hidradenitis suppurativa, from creams to tablets and injections.
13 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie
- Location
- Omaha, NE + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Omaha, NE + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie
- Location
- Omaha, NE + 29 other US sites
- Eligibility basics
- Ages 12–63
- RecruitingPhase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
- Location
- Bellevue, NE + 17 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Omaha, NE + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Novartis Pharmaceuticals
- Location
- Omaha, NE + 23 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Omaha, NE + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 2
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Oruka Therapeutics, Inc.
- Location
- Omaha, NE + 13 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Omaha, NE + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Beijing InnoCare Pharma Tech Co., Ltd.
- Location
- Omaha, NE + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Omaha, NE + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Study of LAD603 in Adults With Alopecia Areata
Almirall, S.A.
- Location
- Omaha, NE
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Omaha, NE + 53 other US sites
- Eligibility basics
- Ages 12–17
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Do I need a diagnosis to join a skin study?
Usually yes, and the site will confirm it at screening. Some studies also recruit people without the condition as a comparison group.